| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARK |
| Uniprot No | O14965 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-403aa |
| 氨基酸序列 | MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRIPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS |
| 预测分子量 | 51.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARK重组蛋白的3篇参考文献示例(注：ARK可能指不同领域蛋白，以下为假设性示例)：
1. **《重组ARK蛋白在细胞凋亡中的功能研究》**
*作者：Zhang L, et al.*
摘要：本研究通过重组表达ARK蛋白，揭示其通过调控线粒体途径促进肿瘤细胞凋亡的机制，为癌症治疗提供新靶点。
2. **《ARK重组蛋白的高效表达与纯化优化》**
*作者：Wang Y, et al.*
摘要：开发了一种基于大肠杆菌的重组ARK蛋白表达系统，通过优化诱导条件和纯化步骤，显著提高蛋白产量与稳定性。
3. **《ARK重组蛋白的结构与酶活性分析》**
*作者：Chen H, et al.*
摘要：利用X射线晶体学解析重组ARK蛋白的三维结构，发现其激酶活性依赖特定的ATP结合域，为药物设计提供结构基础。
建议通过PubMed或Google Scholar以“ARK recombinant protein”“Apoptosis-related kinase expression”等关键词检索最新文献，以获取领域内具体研究。
**Background of ARK Recombinant Proteins**
ARK recombinant proteins are engineered versions of Activin Receptor-like Kinases (ALKs), a subgroup within the transforming growth factor-beta (TGF-β) receptor family. These transmembrane serine/threonine kinases play pivotal roles in cellular signaling pathways, particularly those regulating cell proliferation, differentiation, apoptosis, and immune responses. ALKs (e.g., ALK1 to ALK7) bind ligands such as TGF-β, activins, and bone morphogenetic proteins (BMPs), initiating downstream Smad-dependent or non-Smad signaling cascades. Dysregulation of ALK signaling is linked to pathologies including cancer, fibrosis, and cardiovascular disorders, making them attractive therapeutic targets.
Recombinant ARK proteins are produced via biotechnological methods, often using mammalian or insect cell systems to ensure proper post-translational modifications and functional activity. These proteins serve as critical tools for studying ALK-ligand interactions, signaling mechanisms, and drug development. For instance, ALK2 (ACVR1) mutants are associated with fibrodysplasia ossificans progressiva (FOP), driving research into inhibitors. Similarly, ALK5 (TGF-β receptor type I) is a focus in cancer and fibrosis studies.
Therapeutic applications include designing kinase inhibitors (e.g., repurposing cancer drugs like Crizotinib for ALK1/2 inhibition) and ligand traps to modulate signaling. Challenges remain in achieving selectivity due to structural similarities among ALKs and minimizing off-target effects. Ongoing research aims to refine ARK recombinant proteins for high-specificity assays, biomarker discovery, and next-generation biologics, emphasizing their dual role in understanding disease biology and advancing precision medicine.
(Word count: 249)
×
